title: Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial.
abstract: OBJECTIVE
  Frovatriptan is a selective 5-HT(1B/1D) agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients.
  
  
  METHODS
  In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate.
  
  
  RESULTS
  Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient.
  
  
  CONCLUSIONS
  These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.
authors.affiliation: Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Heui-Soo
authors.initials: HS
authors.lastname: Moon
authors.forename: Min Kyung
authors.initials: MK
authors.lastname: Chu
authors.forename: Jeong Wook
authors.initials: JW
authors.lastname: Park
authors.forename: Kyungmi
authors.initials: K
authors.lastname: Oh
authors.forename: Jae Myun
authors.initials: JM
authors.lastname: Chung
authors.forename: Yong Jin
authors.initials: YJ
authors.lastname: Cho
authors.forename: Eung Gyu
authors.initials: EG
authors.lastname: Kim
authors.forename: Jin Kuk
authors.initials: JK
authors.lastname: Do
authors.forename: Hyong Gi
authors.initials: HG
authors.lastname: Jung
authors.forename: Sun Uck
authors.initials: SU
authors.lastname: Kwon
references.citation: Headache. 2002 Jan;42(1):41-8
references.pmid: 12005274
references.citation: Headache. 1998 Mar;38(3):184-90
references.pmid: 9563208
references.citation: J Chin Med Assoc. 2007 Feb;70(2):39-46
references.pmid: 17339143
references.citation: Headache. 2002 Apr;42 Suppl 2:S84-92
references.pmid: 12028324
references.citation: Headache. 2002 Apr;42 Suppl 2:S74-83
references.pmid: 12028323
references.citation: Cephalalgia. 1993 Jun;13(3):151-65
references.pmid: 8395342
references.citation: Lancet. 2001 Nov 17;358(9294):1668-75
references.pmid: 11728541
references.citation: Drugs. 2000 Dec;60(6):1259-87
references.pmid: 11152011
references.citation: Eur J Clin Pharmacol. 2002 Jul;58(4):247-52
references.pmid: 12136370
references.citation: J Clin Neurol. 2007 Sep;3(3):127-32
references.pmid: 19513279
references.citation: Clin Ther. 2000 Aug;22(8):970-80
references.pmid: 10972633
references.citation: Cephalalgia. 2002 Jun;22(5):376-83
references.pmid: 12110113
references.citation: Neurology. 2004 Jul 27;63(2):261-9
references.pmid: 15277618
references.citation: Cephalalgia. 2004;24 Suppl 1:9-160
references.pmid: 14979299
references.citation: Neurology. 1997 Nov;49(5):1210-8
references.pmid: 9371896
references.citation: Curr Med Res Opin. 2004 Mar;20(3):269-77
references.pmid: 15025836